Prevail Therapeutics Inc.

$23.00 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Join the waitlist

About Prevail Therapeutics Inc.

Prevail Therapeutics Inc. is a gene therapy company. The Company is developing and commercializing adeno-associated virus (AAV)-based gene therapies for patients with neurodegenerative diseases. It is engaged in applying a precision medicine approach to neurodegeneration by studying its gene therapies in genetically defined patient populations. The Company’s lead program is PR001 for the treatment of Parkinson’s disease with gaucher disease mutation, and neuronopathic gaucher disease. The Company is focused on developing a broad pipeline of gene therapies for a range of neurodegenerative diseases, including PR006 for the treatment of frontotemporal dementia with GRN mutation and PR004 for the treatment of synucleinopathies.

Stock Analysis

last close -
1-mo return -
3-mo return -
avg daily vol. -
52-week high -
52-week low -
market cap. -
forward pe -
annual div. -
roe -
ltg forecast -
dividend yield -
annual rev. -
inst own. -
baraka

Join the waitlist for early access and a chance to earn $50 in free stock

Join the waitlist